Boehringer Ingelheim donated the clonidine research medication, and Bayer Pharma the aspirin study drug; both businesses were given a copy of the original draft of the manuscript. However, no donor or funder of the POISE-2 trial experienced any role in the look or conduct of the trial, the analyses or collection of the data, or the composing of the manuscript. The functions committee designed the trial and prespecified the statistical evaluation plan, and the users of that committee vouch for the info and analyses and for the fidelity of the study to the protocol . The initial author wrote the first draft of the manuscript, and all of the authors made substantive revisions and made the decision to send the manuscript for publication.However, the genetic variant is associated with pre-eclampsia when the pregnant mother is obese or overweight. Related StoriesDiscovery may open up new doors to focusing on how melanoma grows and spreadsResearchers determine inherited gene variation associated with pediatric acute lymphoblastic leukemiaPerisylvian polymicrogyria gene found Having the ability to predict which women are at risk of pre-eclampsia is a very important objective in obstetrics, says Professor Claire Roberts from the University of Adelaide's Robinson Institute. Professor Roberts, Dr Ang Professor and Zhou Gus Dekker from the Robinson Institute studied data from the SCOPE study, involving more than 2000 females and their companions in Adelaide, Auckland and Australia, New Zealand. Females who developed pre-eclampsia who had been also obese or obese were twice as likely to carry the AGT2R gene variant compared to the common form of the gene.